- Home
- DFDV vs TNXP Comparison
DFDV vs TNXP Comparison
Compare DFDV & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFDV
- TNXP
- Stock Information
- Founded
- DFDV 2018
- TNXP 2007
- Country
- DFDV United States
- TNXP United States
- Employees
- DFDV N/A
- TNXP N/A
- Industry
- DFDV Finance: Consumer Services
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- DFDV Finance
- TNXP Health Care
- Exchange
- DFDV Nasdaq
- TNXP Nasdaq
- Market Cap
- DFDV 219.8M
- TNXP 197.9M
- IPO Year
- DFDV N/A
- TNXP N/A
- Fundamental
- Price
- DFDV $7.55
- TNXP $15.12
- Analyst Decision
- DFDV Buy
- TNXP Buy
- Analyst Count
- DFDV 1
- TNXP 1
- Target Price
- DFDV $45.00
- TNXP $70.00
- AVG Volume (30 Days)
- DFDV 1.7M
- TNXP 792.7K
- Earning Date
- DFDV 11-12-2025
- TNXP 11-10-2025
- Dividend Yield
- DFDV N/A
- TNXP N/A
- EPS Growth
- DFDV N/A
- TNXP N/A
- EPS
- DFDV 4.13
- TNXP N/A
- Revenue
- DFDV $7,526,660.00
- TNXP $10,299,000.00
- Revenue This Year
- DFDV $312.92
- TNXP $14.79
- Revenue Next Year
- DFDV $141.18
- TNXP $933.49
- P/E Ratio
- DFDV $1.81
- TNXP N/A
- Revenue Growth
- DFDV 313.28
- TNXP N/A
- 52 Week Low
- DFDV $0.53
- TNXP $6.76
- 52 Week High
- DFDV $53.88
- TNXP $130.00
- Technical
- Relative Strength Index (RSI)
- DFDV 35.78
- TNXP 35.51
- Support Level
- DFDV $6.02
- TNXP $13.70
- Resistance Level
- DFDV $7.75
- TNXP $18.25
- Average True Range (ATR)
- DFDV 0.74
- TNXP 1.28
- MACD
- DFDV 0.18
- TNXP 0.07
- Stochastic Oscillator
- DFDV 51.42
- TNXP 26.08
About DFDV DeFi Development Corp. Common Stock
DeFi Development Corp is an AI-powered online platform that connects the commercial real estate industry by providing data and software subscriptions as well as value-add services to multifamily and commercial property professionals.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.